Literature DB >> 36073220

[Honokiol reduces doxorubicin-induced cardiotoxicity in vitro by inhibiting pyroptosis via activating AMPK/Nrf2 signaling].

F Xiong1, R Liu2, Y Li1, N Sun3.   

Abstract

OBJECTIVE: To investigate the effect of honokiol (HKL) for reducing doxorubicin (DOX)-induced cardiotoxicity in H9c2 cells and the underlying mechanisms.
METHODS: H9c2 cells were divided into control group, DOX group, HKL + DOX group, and HKL+compound C+DOX group. After 24 h of corresponding treatment, the cells were examined for morphological changes and cell viability using CCK-8 assay. The mRNA expressions of the inflammatory factors including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1β (IL-1β) were detected by RT-PCR, and the protein levels of cleaved caspase-3, cytochrome c, NOD-like receptor pyrin domain containing 3 (NLRP3), caspase-1, apoptosis-associated speck-like protein containing a CARD (ASC), p-AMPK and nuclear factor (erythroid-derived 2)-like 2 (Nrf2) were detected with Western blotting; the expressions of NLRP3 and p-AMPK also detected with immunofluorescence staining.
RESULTS: DOX treatment caused swelling and significantly lowered the viability of H9c2 cells (P < 0.05), resulting also in increased mRNA expressions of TNF-α, IL-6 and IL-1β (P < 0.05) and protein expressions of cleaved caspase-3, cytochrome c, NLRP3, caspase-1 and ASC (P < 0.05) but reduced protein levels of p-AMPK and Nrf2 (P < 0.05); fluorescence staining showed significantly increased NLRP3 expression and decreased expression of p-AMPK in DOX-treated cells (P < 0.05). All these changes in COX-treated cells were significantly alleviated by HKL treatment (P < 0.05). The application of compound C obviously mitigated the protective effects of HKL against DOX-induced cardiotoxicity in H9c2 cells.
CONCLUSIONS: HKL can alleviate DOX-induced cardiotoxicity by inhibiting pyroptosis in H9c2 cells, and this effect is mediated by activation of AMPK to regulate Nrf2 signaling.

Entities:  

Keywords:  cardiotoxicity; doxorubicin; honokiol; pyroptosis

Mesh:

Substances:

Year:  2022        PMID: 36073220      PMCID: PMC9458529          DOI: 10.12122/j.issn.1673-4254.2022.08.13

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  31 in total

1.  [Changes of cholinergic nerves and tumor necrosis factor-α in doxorubicin-induced rat failing heart].

Authors:  Xiaoli Xu; Jurong Zeng; Xiaojiang Yu; Man Mi; Jin Hou; Lei Sun; Dongling Li; Weijin Zang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2012-08

Review 2.  Targeting the NLRP3 inflammasome in cardiovascular diseases.

Authors:  Stefano Toldo; Eleonora Mezzaroma; Leo F Buckley; Nicola Potere; Marcello Di Nisio; Giuseppe Biondi-Zoccai; Benjamin W Van Tassell; Antonio Abbate
Journal:  Pharmacol Ther       Date:  2021-12-11       Impact factor: 13.400

Review 3.  Honokiol: A review of its pharmacological potential and therapeutic insights.

Authors:  Abdur Rauf; Ahmed Olatunde; Muhammad Imran; Fahad A Alhumaydhi; Abdullah S M Aljohani; Shahid Ali Khan; Md Sahab Uddin; Saikat Mitra; Talha Bin Emran; Mars Khayrullin; Maksim Rebezov; Mohammad Amjad Kamal; Mohammad Ali Shariati
Journal:  Phytomedicine       Date:  2021-07-16       Impact factor: 5.340

Review 4.  Targeting AMPK by Statins: A Potential Therapeutic Approach.

Authors:  Sajad Dehnavi; Amirhossein Kiani; Mahvash Sadeghi; Ali Farhadi Biregani; Maciej Banach; Stephen L Atkin; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Drugs       Date:  2021-05-03       Impact factor: 9.546

5.  Doxorubicin-induced cardiomyocyte death is mediated by unchecked mitochondrial fission and mitophagy.

Authors:  Michael P Catanzaro; Ashley Weiner; Amanda Kaminaris; Cairong Li; Fei Cai; Fengyi Zhao; Satoru Kobayashi; Tamayo Kobayashi; Yuan Huang; Hiromi Sesaki; Qiangrong Liang
Journal:  FASEB J       Date:  2019-07-10       Impact factor: 5.834

6.  Terminalia bellirica (Gaertn.) Roxb. Extract and Gallic Acid Attenuate LPS-Induced Inflammation and Oxidative Stress via MAPK/NF-κB and Akt/AMPK/Nrf2 Pathways.

Authors:  Miori Tanaka; Yoshimi Kishimoto; Mizuho Sasaki; Akari Sato; Tomoyasu Kamiya; Kazuo Kondo; Kaoruko Iida
Journal:  Oxid Med Cell Longev       Date:  2018-11-08       Impact factor: 6.543

7.  PI3Kα Pathway Inhibition With Doxorubicin Treatment Results in Distinct Biventricular Atrophy and Remodeling With Right Ventricular Dysfunction.

Authors:  Brent A McLean; Vaibhav B Patel; Pavel Zhabyeyev; Xueyi Chen; Ratnadeep Basu; Faqi Wang; Saumya Shah; Bart Vanhaesebroeck; Gavin Y Oudit
Journal:  J Am Heart Assoc       Date:  2019-05-07       Impact factor: 5.501

Review 8.  Molecular Mechanisms of Cardiomyocyte Death in Drug-Induced Cardiotoxicity.

Authors:  Wanjun Ma; Shanshan Wei; Bikui Zhang; Wenqun Li
Journal:  Front Cell Dev Biol       Date:  2020-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.